Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05607680
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status Completed
Phase Phase 3
Start date November 14, 2022
Completion date April 16, 2024

See also
  Status Clinical Trial Phase
Completed NCT03629301 - Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults N/A
Completed NCT05153590 - A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
Recruiting NCT05996848 - A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Phase 3
Recruiting NCT05813925 - A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Phase 3